Aktienanalyse zu Redhill Biopharma Ltd (RDHL)RDHLRedhill Biopharma Ltd

RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Redhill Biopharma Ltd is currently not a strong buy due to its significant financial challenges, including a current price of $0.43 and a forward P/E ratio of 1428.57, indicating extreme valuation concerns. The company has reported a year-to-date change of -58.25%, which reflects its ongoing struggles in the market. While there is potential upside with a projected trajectory of +40.45% based on historical patterns, the risks are substantial, particularly given the negative net income of -2066500.00 USD for both Q1 and Q2 of 2025. Investors should be cautious and consider holding their position rather than buying more at this time.

4 analysts cover RDHL: 4 rate it Buy, 0 Hold and 0 Sell.